Literature DB >> 15016879

Correlation between env V1/V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques.

Brian J Rybarczyk1, David Montefiori, Philip R Johnson, Ande West, Robert E Johnston, Ronald Swanstrom.   

Abstract

Evolution of the domain encoding the V1/V2 variable region of the simian immunodeficiency virus sm (SIVsm) envelope (env) gene was analyzed in relation to route of virus challenge, virus load, and neutralizing antibody (NAb) titers during primary infection of rhesus macaques with the pathogenic SIVsmE660 isolate. In this model system animals are initially infected with multiple viruses as evidenced by the presence of multiple V1/V2 genotypic variants that could be resolved by using a heteroduplex tracking assay (HTA). Overlapping subsets of the multiple variants were established in each animal. There was no selection for the establishment of specific variants in comparing intravenous- and intrarectal-challenged macaques at week 2 postinfection, suggesting that no genotypic selection occurred at the mucosal surface. There was an initial period of significant stability of the V1/V2 variants. Macaques challenged intravenously displayed subsequent V1/V2 diversification significantly earlier than macaques challenged intrarectally and well past the initial resolution of viremia. The time when SIVsmE660-specific NAbs reached a threshold titer of 100 was significantly correlated with the timing of V1/V2 diversification, even though antibodies to the Env protein could be detected much earlier. The time when NAbs reached a titer of 400 was significantly correlated with virus load late in infection. These results show that the route of infection affects the timing of V1/V2 diversification and that this diversification is correlated with the maturation of a specific NAb response. However, prior immunization capable of priming an anamnestic Env antibody response did not accelerate V1/V2 diversification. This result suggests that diversification of the SIV env V1/V2 region is the result of a type-specific antibody response.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15016879      PMCID: PMC371075          DOI: 10.1128/jvi.78.7.3561-3571.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  57 in total

Review 1.  Envelope sequence variation, neutralizing antibodies, and primate lentivirus persistence.

Authors:  D P Burns; R C Desrosiers
Journal:  Curr Top Microbiol Immunol       Date:  1994       Impact factor: 4.291

2.  Immune escape by human immunodeficiency virus type 1 from neutralizing antibodies: evidence for multiple pathways.

Authors:  B A Watkins; M S Reitz; C A Wilson; K Aldrich; A E Davis; M Robert-Guroff
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

3.  Insertion of N-linked glycosylation sites in the variable regions of the human immunodeficiency virus type 1 surface glycoprotein through AAT triplet reiteration.

Authors:  M L Bosch; A C Andeweg; R Schipper; M Kenter
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

4.  Human immunodeficiency virus type 1 genetic evolution in children with different rates of development of disease.

Authors:  S Ganeshan; R E Dickover; B T Korber; Y J Bryson; S M Wolinsky
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

5.  Enhanced expression of human immunodeficiency virus type 1 correlates with development of AIDS.

Authors:  P Gupta; L Kingsley; J Armstrong; M Ding; M Cottrill; C Rinaldo
Journal:  Virology       Date:  1993-10       Impact factor: 3.616

6.  Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120.

Authors:  J A McKeating; C Shotton; J Cordell; S Graham; P Balfe; N Sullivan; M Charles; M Page; A Bolmstedt; S Olofsson
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

7.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

8.  Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection.

Authors:  P Borrow; H Lewicki; B H Hahn; G M Shaw; M B Oldstone
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

9.  Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.

Authors:  C Moog; H J Fleury; I Pellegrin; A Kirn; A M Aubertin
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

10.  Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope protein.

Authors:  K Javaherian; A J Langlois; D C Montefiori; K A Kent; K A Ryan; P D Wyman; J Stott; D P Bolognesi; M Murphey-Corb; G J Larosa
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

View more
  22 in total

1.  Independent evolution of human immunodeficiency virus type 1 env V1/V2 and V4/V5 hypervariable regions during chronic infection.

Authors:  Patrick R Harrington; Julie A E Nelson; Kathryn M Kitrinos; Ronald Swanstrom
Journal:  J Virol       Date:  2007-02-28       Impact factor: 5.103

2.  Envelope variable region 4 is the first target of neutralizing antibodies in early simian immunodeficiency virus mac251 infection of rhesus monkeys.

Authors:  Wendy W Yeh; Laura M Brassard; Caroline A Miller; Aravind Basavapathruni; Jinrong Zhang; Srinivas S Rao; Gary J Nabel; John R Mascola; Norman L Letvin; Michael S Seaman
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

3.  Autologous neutralizing antibodies to the transmitted/founder viruses emerge late after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys.

Authors:  Wendy W Yeh; Ishita Rahman; Peter Hraber; Rory T Coffey; Daiva Nevidomskyte; Ayush Giri; Mohammed Asmal; Svetlana Miljkovic; Marcus Daniels; James B Whitney; Brandon F Keele; Beatrice H Hahn; Bette T Korber; George M Shaw; Michael S Seaman; Norman L Letvin
Journal:  J Virol       Date:  2010-03-31       Impact factor: 5.103

4.  Selection of a rare neutralization-resistant variant following passive transfer of convalescent immune plasma in equine infectious anemia virus-challenged SCID horses.

Authors:  Sandra D Taylor; Steven R Leib; Susan Carpenter; Robert H Mealey
Journal:  J Virol       Date:  2010-04-14       Impact factor: 5.103

5.  Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.

Authors:  D Noah Sather; Jakob Armann; Lance K Ching; Angeliki Mavrantoni; George Sellhorn; Zachary Caldwell; Xuesong Yu; Blake Wood; Steve Self; Spyros Kalams; Leonidas Stamatatos
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

6.  Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1.

Authors:  Kimberly Ritola; Christopher D Pilcher; Susan A Fiscus; Noah G Hoffman; Julie A E Nelson; Kathryn M Kitrinos; Charles B Hicks; Joseph J Eron; Ronald Swanstrom
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

7.  Rapid, complex adaptation of transmitted HIV-1 full-length genomes in subtype C-infected individuals with differing disease progression.

Authors:  Melissa-Rose Abrahams; Florette K Treurnicht; Nobubelo K Ngandu; Sarah A Goodier; Jinny C Marais; Helba Bredell; Ruwayhida Thebus; Debra de Assis Rosa; Koleka Mlisana; Cathal Seoighe; Salim Abdool Karim; Clive M Gray; Carolyn Williamson
Journal:  AIDS       Date:  2013-02-20       Impact factor: 4.177

Review 8.  Acute HIV revisited: new opportunities for treatment and prevention.

Authors:  Christopher D Pilcher; Joseph J Eron; Shannon Galvin; Cynthia Gay; Myron S Cohen
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

9.  A rapid progressor-specific variant clone of simian immunodeficiency virus replicates efficiently in vivo only in the absence of immune responses.

Authors:  Takeo Kuwata; Russell Byrum; Sonya Whitted; Robert Goeken; Alicia Buckler-White; Ronald Plishka; Ranjini Iyengar; Vanessa M Hirsch
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103

10.  Nef gene evolution from a single transmitted strain in acute SIV infection.

Authors:  Benjamin N Bimber; Pauline Chugh; Elena E Giorgi; Baek Kim; Anthony L Almudevar; Stephen Dewhurst; David H O'Connor; Ha Youn Lee
Journal:  Retrovirology       Date:  2009-06-08       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.